Publications

5803 Results

Afatinib plus cetuximab versus afatinib alone for first-line treatment of EGFR-mutant non-small cell lung cancer: final results from SWOG S1403

Authors
S Goldberg;M Redman;R Lilenbaum;K Politi;T Stinchcombe;L Horn;E Chen;S Mashru;S Gettinger;M Melnick;R Herbst;M Baumgart;J Miao;J Moon;K Kelly;D Gandara
Journal / Conference
Journal of Clinical Oncology Dec 1;38(34):4076-4085; Oct 6;JCO2001149. doi: 10.1200/JCO.20.01149. Online ahead of print
Year
2020
Research Committee(s)
Lung
PMID
PMID33021871
PMC
PMC7768342
Study Number(s)
S1403

Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial

Authors
A Bryce;Y Chen;G Liu;M Carducci;D Jarrard;J Garcia;R Dreicer;M Hussain;M Eisenberger;E Plimack;N Vogelzang;R DiPaola;L Harshman;C Sweeney
Journal / Conference
European Urology Oncology Dec;3(6):717-724
Year
2020
Research Committee(s)
Genitourinary
PMID
PMID32807727
PMC
PMC7738423
Study Number(s)
CTSU/E3805

Race-dependent differences in risk, genomics and Epstein-Barr virus exposure in monoclonal gammopathies (SWOG S0120)

Authors
M Dhodapkar;R Sexton;A Hoering;F van Rhee;B Barlogie;RZ Orlowski
Journal / Conference
Clinical Cancer Research Nov 15;26(22):5814-5819
Year
2020
Research Committee(s)
Myeloma
PMID
PMID32816893
PMC
PMC7679008
Study Number(s)
S0120

Reply to LTE, Interim PET assessment of advanced Hodgkin Lymphoma: is it sufficient? [Letter to Editor]

Authors
D Stephens;H Schoder;H Li;J Friedberg
Journal / Conference
Journal of Nuclear Medicine Sep 11;jnumed.120.242685. doi: 10.2967/jnumed.120.242685. Online ahead of print.
Year
2020
Research Committee(s)
Lymphoma
PMID
PMID32917781
Study Number(s)
S0816, S1826

Reply to Hawkes et al. [Correspondence]

Authors
D Persky;S Smith;M LeBlanc;J Friedberg
Journal / Conference
Journal of Clinical Oncology Oct 26;JCO2002856. doi: 10.1200/JCO.20.02856. Online ahead of print, 2020.
Year
2020
Research Committee(s)
Lymphoma
PMID
PMID33104437
Study Number(s)
S1001

Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704

Authors
D Bitterman;K Winter;T Hong;C Fuchs;W Regine;R Abrams;H Safran;J Hoffman;A Benson;T Kasunic;M Mulcahy;T DiPetrillo;P Stella;Y Chen;J Plastaras;C Crane
Journal / Conference
International Journal of Radiation Oncology Biology Physics (IJROBP) Aug 26;S0360-3016(20)34137-7. doi: 10.1016/j.ijrobp.2020.08.042.
Year
2020
Research Committee(s)
Gastrointestinal
PMID
PMID32858111
PMC
PMC7736166
Study Number(s)
R9704

Impact of Adjuvant Trastuzumab on Locoregional Failure Rates in the NCCTG N9831 (Alliance) Study

Authors
C Vargas;C Thorpe;A Dueck;K Tenner;E Perez;E Hwang;M Halyard;T Pisansky;N Davidson;S Martino;B Pockaj
Journal / Conference
Cancer Sep 15. doi: 10.1002/cncr.33154. Online ahead of print.
Year
2020
Research Committee(s)
Breast
PMC
PMID32931029
Study Number(s)
N9831

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer

Authors
A Fernandez-Martinez;J Kropf;D Hillman;M-Yin;J Parker;L Huebner;K Hoadley;J Sheperd;S Tolaney;NL Henry;C Dang;L Harris;D Berry;O Hahn;C Hudis;E Winer;A Partridge;C Perou;L Carey
Journal / Conference
Journal of Clinical Oncology Dec 10;38(35):4184-4193.
Year
2020
Research Committee(s)
Breast
PMID
PMID33095682
PMC
PMC7723687

CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE VERSUS BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE FOR INITIAL THERAPY OF NEWLY DIAGNOSED MULTIPLE MYELOMA (ENDURANCE): A PHASE 3 TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E1A11)

Authors
S Kumar;S Jacobus;A Cohen;M Weiss;N Callander;A Singh;T Parker;A Menter;A Yang;B Parsons;P Kumar;P Kapoor;A Rosenberg;J Zonder;E Faber;S Lonial;P Richardson;R Orlowski;L Wagner;S Rajkumar
Journal / Conference
Lancet Oncology Oct;21(10):1317-1330
Year
2020
Research Committee(s)
Myeloma
PMID
PMID32866432
PMC
PMC7591827
Study Number(s)
CTSU/E1A11

A multicenter phase II trial (SWOG S1609, Cohort 51) of Ipilimumab and Nivolumab in metastatic or unresectable angiosarcoma: a sub-study of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Authors
M Wagner;M Othus;S Patel;C Ryan;A Sangal;B Powers;GT Budd;A Victor;C-T Hsueh;R Chugh;E Mayerson;M Plets;CD Blanke;H Streicher;YK Chae;R Kurzrock
Journal / Conference
Journal for ImmunoTherapy of Cancer Nov, 8 (Suppl 3) A843; Society for Immunotherapy of Cancer (SITC) Annual Meeting (November 10-15, 2020, virtual), oral presentation
Year
2020
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609